Today: 19 April 2026
Glencore stock rises as Rio output beat keeps merger spotlight on miners
21 January 2026
1 min read

Glencore stock rises as Rio output beat keeps merger spotlight on miners

London, Jan 21, 2026, 08:41 GMT — Regular session

  • Glencore shares climbed roughly 1.7% in early London trading, defying the weaker trend across European markets.
  • Rio Tinto’s stronger-than-expected output has reignited speculation around takeover discussions and when a deal might unfold.
  • Traders have their eyes on Glencore’s production report set for Jan. 29 and the Feb. 5 takeover-code deadline involving Rio.

Glencore (GLEN.L) shares jumped 1.7% to 490.25 pence early Wednesday, rebounding after Tuesday’s finish at 482.00 pence.

This shift drew attention since the stock now serves as a barometer for merger risk following Rio Tinto’s recent operating update, despite broader European equities falling amid fresh trade tension news.

Rio reported iron ore and copper output in the fourth quarter that exceeded analysts’ expectations. New CEO Simon Trott highlighted the “exceptional production performance” amid ongoing internal restructuring. The company is also in discussions with Glencore over a possible merger. investments.halifax.co.uk

Copper prices remained in the spotlight. On Jan. 21, copper climbed to roughly $5.87 per pound, according to Trading Economics data.

Glencore’s shares fluctuated between 480.86 pence and 490.95 pence during the session, with roughly 2.7 million shares changing hands, based on delayed quotes from Hargreaves Lansdown.

Deal-watchers have been closely analyzing a steady stream of “Form 8.3” disclosures — filings mandated by the UK Takeover Code for investors holding 1% or more to report their stakes and trades during an offer period. Rio Tinto

Glencore has two key dates lined up: its full-year production report is set for Jan. 29, followed by the full-year earnings release on Feb. 18, the company confirmed.

On the Rio-Glencore front, the UK timeline is narrower. Rio must spell out its plans by Feb. 5 under takeover regulations, Reuters reports.

Still, there’s a major “but.” The talks might collapse, and if a deal does emerge, it would face a tougher market environment—especially if trade tensions escalate or metal prices slip. That leaves Glencore vulnerable after a recent surge.

Focus now turns to Jan. 29, when Glencore is set to release its production report, followed by Rio’s deadline on Feb. 5 — both dates with the potential to rapidly shift market expectations.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
BP share price today: BP stock edges up after buyback update as oil prices slip
Previous Story

BP share price today: BP stock edges up after buyback update as oil prices slip

United Airlines stock pops in premarket after UAL lifts 2026 profit outlook — what investors watch next
Next Story

United Airlines stock pops in premarket after UAL lifts 2026 profit outlook — what investors watch next

Go toTop